Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9607 posts found.

merck kgaa image

Merck KGaA licences new cancer candidate

September 10, 2012 Research and Development, Sales and Marketing Cancer, EGFR, Merck KGaA, oncology

Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …
News

New product launches – maximise your chance of success

September 6, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSI, Paul Stuart Kregor, Paul Stuart-Kregor, marketing, product launch

You don’t have to look very far to see that the pharma industry business model is under increased pressure, and …
Feature

Merck KGaA cuts over 10% of German workforce

September 5, 2012 Research and Development

Merck KGaA is to get rid of more than 10% of its workforce in Germany over the next three years …
News

Pharma welcomes Hunt to top health job

September 5, 2012 Research and Development, Sales and Marketing Andrew Lansley, NHS, NHS reform

The ABPI has used health secretary Andrew Lansley’s demotion at prime minister David Cameron’s first major cabinet reshuffle to restate …
News

Pfizer to develop phase II cancer vaccine

September 4, 2012 Research and Development, Sales and Marketing Cancer, Pfizer, VLST, cancer vaccine

Pfizer has licensed a cancer compound which is ready for phase II study from a US firm specialising in cancer …
News

Contract research news in brief

September 4, 2012 Research and Development CRO, Charles River, WuXi

 Charles River Laboratories (CRL) has paid $17 million for Accugenix, a company which provides endotoxin detection and microbial identity testing …
News
Novartis

Novartis cheered by COPD trial results

September 3, 2012 Research and Development COPD, ERS, Novartis

One of Novartis’ experimental respiratory drugs has proved superior in a late-stage trial to Boehringer Ingelheim and Pfizer’s existing brand …
News

Allergan signs $1.5 billion deal with Molecular Partners

August 22, 2012 Research and Development, Sales and Marketing Allergan, Molecular Partners, eye diseases

Allergan has signed a deal potentially worth $1.5 billion with Molecular Partners to develop new drugs for certain eye diseases. …
News
screen_shot_2012-08-22_at_09

Lundbeck makes two senior appointments

August 22, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Eggert, Klaus Abel, Lundbeck

Lundbeck has appointed Andreas Eggert (pictured) as senior vice president for global product strategy, and Klaus Abel as vice president …
Appointment

Pfizer’s arthritis drug delayed by FDA

August 21, 2012 Research and Development, Sales and Marketing FDA, Pfizer, tofacitinib

Pfizer says its new rheumatoid arthritis drug tofacitinib has been delayed by the FDA. Tofacitinib, an oral Janus kinase (JAK) …
News
screen_shot_2012-08-21_at_09

INC Research promotes Jamie Macdonald to chief executive

August 21, 2012 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing INC Research, Jamie Macdonald

Clinical research organisation INC Research has announced chief operating officer Jamie Macdonald will become the firm’s next president and chief …
Appointment

GSK severe asthma drug progresses to Phase III

August 20, 2012 Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III

GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …
News

Zaicom MMC appoints new medical writer

August 17, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Katharine Peregrín, Zaicom MMC

Comms agency Zaicom MMC, part of the Zaicom International group of companies, has appointed Katharine Peregrín as a medical writer.  …
Appointment

The number one reason for a failed project

August 16, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Communication, Failed project, Les Rose, clinical trials

There was once a company that had an amusing form of words for admonishing people. It went something like this: …
Feature
Tsyabri image

Elan to spin off drug discovery arm

August 14, 2012 Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis

Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …
News
The Gateway to Local Adoption Series

Latest content

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026

Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer

March 23, 2026